Source: Marvel Biosciences.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Marvel Biosciences (MRVL) has completed a manufacturing milestone required to begin Phase 1 human trials targeting Alzheimer’s disease and depression
  • The company successfully completed a multi-kilogram scale run under current good manufacturing practices (cGMP) of the active pharmaceutical ingredient (API) of the company’s lead asset MB-204
  • Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development
  • Marvel Biosciences Corp. was unchanged at $0.125 at 12:49 PM ET

Marvel Biosciences (MRVL) has completed a manufacturing milestone required to begin Phase 1 human trials targeting Alzheimer’s disease and depression.

Marvel Biosciences Corp., with its wholly-owned subsidiary, Marvel Biotechnology Inc. successfully completed a multi-kilogram scale run under current good manufacturing practices (cGMP) of the active pharmaceutical ingredient (API) of the company’s lead asset MB-204.

Marvel completed the milestone in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd.

The cGMP material obtained from this study will be utilized in the company’s upcoming Phase 1 clinical study.

“We are pleased to have achieved yet another manufacturing milestone in producing clinical grade MB-204 API with our manufacturing partner Ausun,” stated Rod Matheson, Chief Executive Officer of Marvel Biosciences.

“We are planning our Phase 1 human trials and we look forward to updating the market with news on our 4-week GLP toxicology studies shortly,” he added.

In the United States, it is estimated that one in 10 senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer’s that has similar properties to the FDA-approved drug Istradefylline.

MB-204 has, through the company’s studies, proven to be more effective and longer lasting, while offering a higher reduction in depression and anxiety symptoms.

Marvel Biosciences Corp., with its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development.

Marvel Biosciences Corp. was unchanged at $0.125 at 12:49 PM ET.


More From The Market Herald

" @ the Bell: Markets tumble amid rate worries

Canada’s main stock index was weighed down on Monday by commodity-linked and financial stocks. The telecom and utilities sectors posted some gains.
Dolly Varden Silver Corporation - President & CEO, Shawn Khunkhun.

" Dolly Varden Silver (TSXV:DV) reports highest-grade silver assay found so far on the Kitsault Valley Property

Dolly Varden Silver Corporation (DV) discovered the highest-grade silver assay found so far on the Kitsault Valley Property.

" Black Tusk Resources (CSE:TUSK) acquiring PegaLith Project

Black Tusk Resources (TUSK) has signed a $361,000 share purchase agreement to acquire 1396427 BC Ltd.

" Deep South Resources (TSXV:DSM) closes oversubscribed non-brokered private placement

Deep-South Resources (DSM) has closed the final tranche of an oversubscribed, non-brokered private placement for gross proceeds of $490,000.